Century Therapeutics (IPSC) Expected to Announce Earnings on Thursday

Century Therapeutics (NASDAQ:IPSC) is projected to post its Q3 2026 results before the market opens on Thursday, November 12th. Analysts expect Century Therapeutics to post earnings of ($0.12) per share and revenue of $1.63 million for the quarter. Investors can find conference call details on the company’s upcoming Q3 2026 earnings results page for the latest details on the call scheduled for Monday, November 9, 2026 at 9:30 AM ET.

Century Therapeutics (NASDAQ:IPSC) last posted its earnings results on Wednesday, August 12th. The company reported ($0.17) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.11) by ($0.06). On average, analysts expect Century Therapeutics to post ($0.51) EPS for the current fiscal year and ($0.51) EPS for the next fiscal year.

Century Therapeutics Stock Up 9.9%

Century Therapeutics stock opened at $1.67 on Thursday. Century Therapeutics has a 52-week low of $0.43 and a 52-week high of $3.04. The firm’s fifty day moving average is $1.70 and its 200 day moving average is $2.08. The company has a market cap of $302.39 million, a price-to-earnings ratio of -1.80 and a beta of 1.78.

Wall Street Analyst Weigh In

A number of analysts have recently weighed in on the stock. Weiss Ratings restated a “sell (d-)” rating on shares of Century Therapeutics in a report on Tuesday, September 29th. Wall Street Zen downgraded shares of Century Therapeutics from a “hold” rating to a “sell” rating in a report on Saturday, October 31st. Four analysts have rated the stock with a Buy rating, two have given a Hold rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the company presently has a consensus rating of “Hold” and an average price target of $4.75.

About Century Therapeutics

Century Therapeutics, Inc is a biotechnology company focused on developing allogeneic, or “off-the-shelf,” cell therapies for cancer. The company uses induced pluripotent stem cell (iPSC) technology to create immune-effector cells, including natural killer (NK) cells and T cells, that can be engineered to recognize and attack tumor cells.

Century’s pipeline has included product candidates designed for hematologic malignancies and solid tumors. Its programs incorporate technologies intended to improve the persistence, activity, and scalability of engineered immune cells, with development efforts involving targets such as CD19 and other tumor-associated antigens.